XML 13 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Balance Sheets - USD ($)
Dec. 31, 2016
Sep. 30, 2016
CURRENT ASSETS    
Cash and cash equivalents $ 102,105,569 $ 85,366,448
Trade receivables 60,000 75,000
Prepaid expenses 569,415 1,289,923
Other current assets 3,495,369 3,771,172
TOTAL CURRENT ASSETS 106,230,353 90,502,543
Property and equipment, net 16,165,659 15,386,761
Intangible assets, net 21,739,761 22,164,868
Other assets 122,333 122,333
TOTAL ASSETS 144,258,106 128,176,505
CURRENT LIABILITIES    
Accounts payable 3,698,297 12,232,906
Accrued expenses 4,762,105 4,587,467
Accrued payroll and benefits 2,150,014 3,969,706
Deferred rent 440,580 440,580
Deferred revenue 25,584,181 2,569,792
Derivative liabilities 118,795 1,602,626
Note Payable 197,713 194,310
Other current liabilities 46,407 46,407
TOTAL CURRENT LIABILITIES 36,998,092 25,643,794
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 2,188,703 2,274,997
Deferred revenue, net of current portion 5,180,115 2,500,000
Note Payable, net of current portion 2,482,775 2,533,455
Other non-current liabilities 200,000 200,000
TOTAL LONG-TERM LIABILITIES 10,051,593 7,508,452
Commitments and contingencies (Note 6)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 15,652 shares issued and outstanding as of December 31, 2016 and September 30, 2016   16
Common stock, $0.001 par value; 145,000,000 shares authorized; 74,413,040 and 69,746,685 shares issued and outstanding as of December 31, 2016 and September 30, 2016, respectively 166,782 162,116
Additional paid-in capital 508,303,137 493,844,909
Accumulated other comprehensive income (loss) (185,159) 7,449
Accumulated deficit (410,521,151) (398,435,043)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 97,763,609 95,579,447
Noncontrolling interest (555,188) (555,188)
TOTAL STOCKHOLDERS’ EQUITY 97,208,421 95,024,259
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 144,258,106 $ 128,176,505